The IRX6 antibody is a research tool targeting the Iroquois homeobox protein 6 (IRX6), a transcription factor encoded by the *IRX6* gene, part of the evolutionarily conserved Iroquois (Irx) gene family. These genes play critical roles in embryonic development, particularly in patterning neural, cardiac, and musculoskeletal systems. IRX6 is characterized by a conserved homeodomain involved in DNA binding and a paired Iro box motif that mediates protein interactions. Studies suggest IRX6 regulates cell differentiation and tissue morphogenesis, with emerging roles in pancreatic development and β-cell function, linking it to diabetes research. Dysregulation of IRX6 has also been implicated in cancers, including colorectal and gastric malignancies, where it may act as an oncogene or tumor suppressor depending on context. The IRX6 antibody is primarily used in biomedical research to detect IRX6 expression and localization via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Its specificity is validated through knockout controls or siRNA-based silencing. While commercial IRX6 antibodies are available, variability in clone performance across species (human, mouse) or tissue types requires careful validation. Current research focuses on clarifying IRX6's molecular mechanisms in development and disease, with potential applications in diagnostics or targeted therapies.